Gland Pharma reappoints MD and CEO for another 5 years

The Board of Directors (the "Board") of Gland Pharma Limited (the "Company") at its Meeting held today, i.e. Thursday, March 10, 2022, have considered and approved the changes in board.

Based on the recommendation of Nomination and Remuneration Committee, the board has approved the re-appointment of Mr. Srinivas Sadu (DIN: 06900659) as Managing Director and CEO of the Company for a period of 5 years, with effect from 25th April, 2022; subject to the approval of Members of the Company.

The board also approved the appointment of Mr. Yao Fang (DIN: 09524705) as an Additional Director, categorized as NonIndependent and Non-Executive Director, with effect from March 10, 2022 as a Director liable to retire by rotation.

The board also approved the resignation of Mr. Li Dongming (DIN: 08047543) with effect from the conclusion of Board Meeting on March 10, 2022.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 3360.00 as compared to the previous close of Rs. 3297.75. The total number of shares traded during the day was 1533 in over 435 trades.

The stock hit an intraday high of Rs. 3380.00 and intraday low of 3317.25. The net turnover during the day was Rs. 5142695.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 BoardChanges Reappointment MD CEO